The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits.
about
Arylbenzazepines are potent modulators for the delayed rectifier K+ channel: a potential mechanism for their neuroprotective effectsFunctional organization of the basal ganglia: Therapeutic implications for Parkinson's diseaseTAK-063, a PDE10A Inhibitor with Balanced Activation of Direct and Indirect Pathways, Provides Potent Antipsychotic-Like Effects in Multiple ParadigmsNeuroprotective effects of atypical D1 receptor agonist SKF83959 are mediated via D1 receptor-dependent inhibition of glycogen synthase kinase-3 beta and a receptor-independent anti-oxidative actionAlpha-synuclein protects cerebellar granule neurons against 6-hydroxydopamine-induced deathPSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor traffickingThe hidden sister of motor fluctuations in Parkinson's disease: A review on nonmotor fluctuations.Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia.In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liabilityDifferent corticostriatal integration in spiny projection neurons from direct and indirect pathwaysPathological basal ganglia activity in movement disorders.The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated ratsClinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors.Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities.Targeting the progression of Parkinson's disease.The basal ganglia in Parkinson's disease: current concepts and unexplained observations.Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management.Synchronized firing of fast-spiking interneurons is critical to maintain balanced firing between direct and indirect pathway neurons of the striatum.Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease.Levodopa in the treatment of Parkinson's disease: an old drug still going strong.Therapeutic options for continuous dopaminergic stimulation in Parkinson's diseaseApomorphine and levodopa infusion therapies for advanced Parkinson's disease.The role of subcutaneous infusion of apomorphine in Parkinson's disease.Preclinical Evidence for a Role of the Nicotinic Cholinergic System in Parkinson's Disease.The effect of L-dopa in Parkinson's disease as revealed by neurophysiological studies of motor and sensory functions.Clinical features, pathophysiology, and treatment of levodopa-induced dyskinesias in Parkinson's disease.Evaluation of blood-brain barrier transport and CNS drug metabolism in diseased and control brain after intravenous L-DOPA in a unilateral rat model of Parkinson's diseaseTherapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo).Effects of early vs. late initiation of levodopa treatment in hemiparkinsonian rats.Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.Influence of hepatic impairment on the pharmacokinetics of the dopamine agonist rotigotine.Intratelencephalic corticostriatal neurons equally excite striatonigral and striatopallidal neurons and their discharge activity is selectively reduced in experimental parkinsonism.Long-term levodopa/carbidopa intestinal gel in advanced Parkinson's disease.Regulation of striatal preproenkephalin mRNA levels in MPTP-lesioned mice treated with estradiol.Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels.Effect of the metabotropic glutamate antagonist MPEP on striatal expression of the Homer family proteins in levodopa-treated hemiparkinsonian rats.The duration of the motor response to apomorphine boluses is conditioned by the length of a prior infusion in Parkinson's disease.Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms.Entacapone in elderly Parkinsonian patients experiencing levodopa-related wearing-off: a pilot study.
P2860
Q21091199-F2C086B7-5887-4999-9EBA-89C7B913B92BQ22252880-024D4E17-43EB-4D0A-96C1-5468A19FC325Q28384192-21C0DBC2-9A90-473C-84C0-B925D36A866DQ28578951-B6117A33-92C2-47D5-8DA6-B476BF1DA9FDQ28582019-C0EB2799-40C5-4D81-9F33-329F9362DDF3Q28582674-FA2A1044-BC86-4F97-B4C9-A5A236D04F50Q30248922-32FCEE80-AC77-4F03-B943-BD3F8526203EQ33255884-1B9A6232-EC97-414F-8D80-097D66662425Q33751118-ADF36131-67E4-468F-8FE1-3E6B82B7195DQ33944484-FF145E11-CA7D-4CAA-BF08-3364AF9ED4F5Q35532146-237F5AF5-F347-4A6C-B3F3-AB4CDEE603BCQ35740152-F2020449-AEDA-4316-8FEC-30DDF0CA06E7Q36107140-500A052C-8AA7-4949-9B84-CA29EB065ED2Q36248857-C4C039B3-918B-4116-9E95-098EEFE730A6Q37264464-C4C25D78-585C-4F6D-BA95-1F98CAFBDD69Q37299619-50C8ED3A-CF58-46E1-AFA4-5C8F29D20FF2Q37363923-126F4E22-010E-4017-9573-F669FF7F3893Q37507973-EB274AEA-7343-473E-8334-DA7BE6EEC818Q37578353-1F821444-1A23-47E5-8D5F-FBE5B9F2DAE8Q37678381-6224A4FE-C0AB-4E23-995C-ADF745E36630Q37790274-32CD662D-0751-4E07-8623-4ED3B4AFACDDQ37823337-8922C7B4-9251-457B-B828-C7CFED5CF25FQ38215506-89DBCBB5-23B7-4D40-B9AC-29663EECB460Q38219351-46841D0A-E05D-43DA-90C5-059A73B492B3Q38629277-B5E558AF-5A2C-47A6-B99E-2597FEEF6987Q38914186-10808EF7-438C-4F1D-92ED-FB936A8D0FC1Q41645312-F89255E6-DC75-47C5-A90B-13304F36CA24Q41814137-98354C30-05B9-428E-B747-657EBA420C6CQ42427666-8B584C37-A602-4CC3-9A84-FF680C75DCFEQ42459099-84D4E535-709C-4DF0-BBFD-EE348DB39CE8Q42492136-102C5533-1208-40D9-AEAD-99E28750C1D9Q45086483-32DAE6FD-3FCF-4AD6-ADB5-C1DFE5B7A075Q45218750-BB53B1F3-7787-4046-88BD-63F81547C45CQ45246047-0ED3C8AF-759C-424C-B552-6D184E6E2D67Q45276522-31BAF679-C5ED-4AC0-A8CD-B05354229B00Q45748694-56805349-3278-4379-AF44-37B9A550C25FQ45918207-8F99633F-A8EB-4C8D-9BA3-8A2136FC1834Q46118575-F460DD06-4D79-40A5-B700-3DD16DA6F4E7Q46418668-9C673938-B3A2-4665-B24A-19593E7920A4Q46437412-1B7E2B23-54D3-4ADB-918F-22B769D1815A
P2860
The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The origin of motor fluctuatio ...... on and basal ganglia circuits.
@ast
The origin of motor fluctuatio ...... on and basal ganglia circuits.
@en
type
label
The origin of motor fluctuatio ...... on and basal ganglia circuits.
@ast
The origin of motor fluctuatio ...... on and basal ganglia circuits.
@en
prefLabel
The origin of motor fluctuatio ...... on and basal ganglia circuits.
@ast
The origin of motor fluctuatio ...... on and basal ganglia circuits.
@en
P2093
P1433
P1476
The origin of motor fluctuatio ...... ion and basal ganglia circuits
@en
P2093
I Zamarbide
M Rodriguez-Diaz
P304
P356
10.1212/WNL.62.1_SUPPL_1.S17
P407
P433
P577
2004-01-01T00:00:00Z